An evaluation of the ability of pifithrin-α and to inhibit -β function in two wild-type p53 human tumor cell lines

被引:57
作者
Walton, MI [1 ]
Wilson, SC [1 ]
Hardcastle, IR [1 ]
Mirza, AR [1 ]
Workman, P [1 ]
机构
[1] Canc Res UK, Ctr Canc Therapeut, Inst Canc Res, Haddow Labs, Sutton SM2 5NG, Surrey, England
关键词
D O I
10.1158/1535-7163.MCT-04-0341
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The small-molecule compound pifithrin-alpha (PFT-alpha) has been reported to inhibit p53 function and protect against a variety of genotoxic agents. We show here that PFT-alpha is unstable in tissue culture medium and is rapidly converted to its condensation product PFT-beta. Both compounds showed limited solubility with PFT-alpha precipitating out of tissue culture medium at concentrations > 30 mu mol/L. PFT-alpha and -beta exhibited cytotoxic effects in vitro towards two human wild-type p53-expressing tumor cell lines, A2780 ovarian and HCT116 colon (IC50 values for both cell lines were 21.3 +/- 8.1 mu mol/L for PFT-alpha and 90.3 +/- 15.5 mu mol/L for PFT-beta, mean +/- SD, n = 4). There was no evidence of protection by clonogenic assay with either compound in combination with ionizing radiation. Indeed, there was some evidence that PFT-alpha enhanced cytotoxicity, particularly at higher concentrations of PFT-alpha. Neither compound had any effect on p53, p21, or MDM-2 protein expression following ionizing radiation exposure and there was no evidence of any abrogation of p53-dependent, ionizing radiation -induced cell cycle arrest. Similarly, there was no evidence of cellular protection, or of effects on p53-dependent gene transcription, or on translation of MDM-2 or p21 following UV treatment of these human tumor cell lines. In addition, there was no effect on p53 or p21 gene transactivation or p38 phosphorylation after UV irradiation of NIH-3T3 mouse fibroblasts. In conclusion, neither PFT-alpha nor -beta can be regarded as a ubiquitous inhibitor of p53 function, and caution should be exercised in the use of these agents as specific p53 inhibitors.
引用
收藏
页码:1369 / 1377
页数:9
相关论文
共 38 条
[31]   p53 Guardian of a Genome's Guardian? [J].
Rubbi, Carlos P. ;
Milner, Jo .
CELL CYCLE, 2003, 2 (01) :18-19
[32]  
Sanchez-Prieto R, 2000, CANCER RES, V60, P2464
[33]   NEW COLORIMETRIC CYTOTOXICITY ASSAY FOR ANTICANCER-DRUG SCREENING [J].
SKEHAN, P ;
STORENG, R ;
SCUDIERO, D ;
MONKS, A ;
MCMAHON, J ;
VISTICA, D ;
WARREN, JT ;
BOKESCH, H ;
KENNEY, S ;
BOYD, MR .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (13) :1107-1112
[34]   Surfing the p53 network [J].
Vogelstein, B ;
Lane, D ;
Levine, AJ .
NATURE, 2000, 408 (6810) :307-310
[35]   Live or let die: The cell's response to p53 [J].
Vousden, KH ;
Lu, X .
NATURE REVIEWS CANCER, 2002, 2 (08) :594-604
[36]  
Westphal CH, 1998, CANCER RES, V58, P5637
[37]  
WILSON AP, 1992, ANIMAL CELL CULTURE, P253
[38]   Novel p53 inactivators with neuroprotective action: Syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-imino-2,3,4,5,6,7-hexahydrobenzoxazole derivatives [J].
Zhu, XX ;
Yu, QS ;
Cutler, RG ;
Culmsee, CW ;
Holloway, HW ;
Lahiri, DK ;
Mattson, MP ;
Greig, NH .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (23) :5090-5097